SWOG clinical trial number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases

Open
Phase
II
Accrual
9%
Abbreviated Title
Sacituzumab Govitecan for HER2-Neg Breast Cancer and Brain Metastases
Status Notes
Activation - Effective 12/15/20, 12:00 PM Pacific Time

All protocol documents will be accessible from the S2007 protocol abstract page on www.ctsu.org after activation on 12/15/20 (login required).
Activated
12/15/2020
Participants
ALL NATIONAL CLINICAL TRIALS NETWORK MEMBERS LISTED ON TITLE PAGE

Research committees

Breast Cancer

Treatment

sacituzumab govitecan

Eligibility Criteria Expand/Collapse

Please see Section 5.0 of the S2007 protocol.

Reports & Approvals

Trial Locations

Other Clinical Trials

SWOG Clinical Trial Number
CTSU/NRG-BR007

A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Research Committee(s)
Breast Cancer
Activated
06/07/2021
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A011801

The COMPASSHER2 Trials (Comprehensive Use of Pathologic Response Assessment to Optimize Therapy in Her2-Positive Breast Cancer): COMPASSHER2 Residual Disease (RD), A Double-Blinded, Phase III Randomized Trial of T-DM1 and Placebo Compared with T-DM1 and Tucatinib
Research Committee(s)
Breast Cancer
Symptom Control and Quality of Life
Activated
01/06/2021
Open
Phase
III
SWOG Clinical Trial Number
S2007

A Phase II Trial of Sacituzumab Govitecan (IMMU-132) (NSC #820016) for Patients with HER2-Negative Breast Cancer and Brain Metastases
Research Committee(s)
Breast Cancer
Activated
12/15/2020
Accrual
9%
Open
Phase
II